MedPath

Findings From COBALT Trial, Including External Control Arm, - GlobeNewswire

Analysis of COBALT trial shows OCA significantly reduces risk of death, liver transplant, and hepatic decompensation in PBC patients compared to non-OCA treated controls, highlighting the importance of external control data in rare disease trials.


Reference News

Findings From COBALT Trial, Including External Control Arm, Published in The American ...

Analysis of COBALT trial in PBC shows OCA significantly reduces risk of death, liver transplant, and hepatic decompensation compared to non-OCA treated patients, emphasizing the value of external control data in rare disease trials.

Findings From COBALT Trial, Including External Control Arm, - GlobeNewswire

Analysis of COBALT trial shows OCA significantly reduces risk of death, liver transplant, and hepatic decompensation in PBC patients compared to non-OCA treated controls, highlighting the importance of external control data in rare disease trials.

© Copyright 2025. All Rights Reserved by MedPath